Bionano Genomics Inc. [NASDAQ: BNGO] slipped around -0.39 points on Monday, while shares priced at $5.17 at the close of the session, down -7.01%. The company report on September 16, 2021 that Study Finds the Combination of Optical Genome Mapping and Short-Read Sequencing Provides a Comprehensive Genome Analysis for Lung Cancer Samples and Enables the Discovery of New Biomarkers.
Bionano Genomics, Inc. (Nasdaq: BNGO) announced a study finding the combination of optical genome mapping (OGM) and short-read next-generation sequencing (NGS) provides a comprehensive genome analysis for lung cancer samples and enables the discovery of new biomarkers. This study, appearing in the September 7th peer-reviewed issue of Cell Reports describes how the combination of OGM and NGS aids in the detection of structural variants (SVs) in non-small cell lung carcinoma (NSCLC), the most common form of lung cancer.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Non-small cell lung carcinoma (NSCLC) is the leading cause of cancer-related death worldwide. Genomic structural variations (SVs), including large indels, inversions, duplications, and translocations, are essential causes of alterations in gene expression and are recognized as hallmarks in tumorigenesis. In this study, recurrently SV-disrupted genes were significantly enriched in cancer-related pathways highlighting the importance of OGM for detecting all classes of SVs. This study utilized short-read NGS and Bionano’s OGM to obtain high-technical-confidence somatic SVs to investigate candidate oncogenes in cancer patients. An essential role of high-technical-confidence somatic SVs guided the identification of two new oncogenes (TRIO and SESTD1) in NSCLC.
Bionano Genomics Inc. stock is now 67.86% up from its year-to-date (YTD) trading value. BNGO Stock saw the intraday high of $5.38 and lowest of $5.06 per share. The company’s 52-week high price is 15.69, which means current price is +32.23% above from all time high which was touched on 02/16/21.
Compared to the average trading volume of 10.33M shares, BNGO reached a trading volume of 12918062 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Bionano Genomics Inc. [BNGO]?
BTIG Research have made an estimate for Bionano Genomics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on June 16, 2021. While these analysts kept the previous recommendation, Ladenburg Thalmann raised their target price to Buy. The new note on the price target was released on September 24, 2020, representing the official price target for Bionano Genomics Inc. stock. Previously, the target price had yet another raise to $1.50, while Oppenheimer analysts kept a Outperform rating on BNGO stock.
The Average True Range (ATR) for Bionano Genomics Inc. is set at 0.29, with the Price to Sales ratio for BNGO stock in the period of the last 12 months amounting to 104.02. The Price to Book ratio for the last quarter was 4.17, with the Price to Cash per share for the same quarter was set at 1.25.
How has BNGO stock performed recently?
Bionano Genomics Inc. [BNGO] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -3.36. With this latest performance, BNGO shares gained by 0.58% in over the last four-week period, additionally sinking by -42.87% over the last 6 months – not to mention a rise of 737.79% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BNGO stock in for the last two-week period is set at 39.83, with the RSI for the last a single of trading hit 37.74, and the three-weeks RSI is set at 41.41 for Bionano Genomics Inc. [BNGO]. The present Moving Average for the last 50 days of trading for this stock 5.80, while it was recorded at 5.30 for the last single week of trading, and 6.67 for the last 200 days.
Bionano Genomics Inc. [BNGO]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Bionano Genomics Inc. [BNGO] shares currently have an operating margin of -435.74 and a Gross Margin at +21.67. Bionano Genomics Inc.’s Net Margin is presently recorded at -483.43.
Return on Total Capital for BNGO is now -98.66, given the latest momentum, and Return on Invested Capital for the company is -149.42. Return on Equity for this stock declined to -212.46, with Return on Assets sitting at -90.69. When it comes to the capital structure of this company, Bionano Genomics Inc. [BNGO] has a Total Debt to Total Equity ratio set at 46.54. Additionally, BNGO Total Debt to Total Capital is recorded at 31.76, with Total Debt to Total Assets ending up at 27.01. Long-Term Debt to Equity for the company is recorded at 46.54, with the Long-Term Debt to Total Capital now at 31.76.
Reflecting on the efficiency of the workforce at the company, Bionano Genomics Inc. [BNGO] managed to generate an average of -$279,635 per employee. Receivables Turnover for the company is 1.87 with a Total Asset Turnover recorded at a value of 0.19.Bionano Genomics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 31.40 and a Current Ratio set at 31.90.
Insider trade positions for Bionano Genomics Inc. [BNGO]
There are presently around $386 million, or 26.90% of BNGO stock, in the hands of institutional investors. The top three institutional holders of BNGO stocks are: BLACKROCK INC. with ownership of 18,332,984, which is approximately 435.816% of the company’s market cap and around 0.30% of the total institutional ownership; VANGUARD GROUP INC, holding 14,855,436 shares of the stock with an approximate value of $76.8 million in BNGO stocks shares; and STATE STREET CORP, currently with $38.86 million in BNGO stock with ownership of nearly 6619.202% of the company’s market capitalization.
Positions in Bionano Genomics Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 111 institutional holders increased their position in Bionano Genomics Inc. [NASDAQ:BNGO] by around 50,882,461 shares. Additionally, 61 investors decreased positions by around 19,455,533 shares, while 24 investors held positions by with 4,305,389 shares. The mentioned changes placed institutional holdings at 74,643,383 shares, according to the latest SEC report filing. BNGO stock had 76 new institutional investments in for a total of 11,354,468 shares, while 34 institutional investors sold positions of 10,954,580 shares during the same period.